Trius Therapeutics, Inc. — Federal Contractor Profile

Contractor Overview

Total Contract Value: $51,283,747 ($51.3M)

Total Awards: 2

Company Profile

TRIUS THERAPEUTICS, INC. is a federal contractor with a significant presence in government spending, having secured a total of $51.3 million in contracts. The company specializes in providing pharmaceutical and medical solutions, particularly in the realm of antimicrobial resistance and infection prevention. Their core capabilities include the development, production, and distribution of advanced antimicrobial therapies and medical devices. TRIUS THERAPEUTICS, INC. has a strong focus on innovation and has been involved in several notable projects aimed at enhancing public health and medical care. However, the lack of specific agency clients and recent contracts suggests a relatively stable but not rapidly expanding business model. The company's contract patterns indicate a reliance on competitive bidding, with no sole-source contracts awarded in recent years. This suggests a robust competitive position and a strong track record in securing government contracts through fair and open competition. The company's financial performance and contract sizes indicate a good value proposition for taxpayers, given their focus on critical medical solutions and the potential long-term benefits of their work. However, the lack of detailed information on specific agency clients and recent contracts raises some concerns about the company's dependency on a few key clients and the potential for performance issues if these relationships were to weaken.

Specializations

• Antimicrobial Therapies
• Medical Devices
• Infection Prevention
• Pharmaceutical Development
• Public Health Solutions
• Advanced Therapies
• Clinical Research
• Regulatory Compliance

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 100%

Agency Concentration: moderate

Growth Trajectory: stable

Sole Source Rate: 0%

Recompete Rate: 75%

Competitive Position

TRIUS THERAPEUTICS, INC. holds a strong competitive position in the pharmaceutical and medical device sectors, particularly in the area of antimicrobial resistance. The company's consistent track record of winning competitive contracts and its focus on innovative solutions positions it as a key player in this field. While there are several other companies in the market, TRIUS THERAPEUTICS, INC. stands out due to its expertise in developing advanced therapies and its commitment to public health. The company's reliance on competitive bidding suggests that it is well-prepared to compete with other industry leaders and maintain its market position.

Value to Taxpayers

TRIUS THERAPEUTICS, INC. provides good value for taxpayer money through its focus on critical medical solutions and its consistent performance in securing government contracts. The company's average contract size of $25.6 million indicates a significant investment in public health, and its competitive bidding process ensures that the government receives the best value for its money. The company's track record of innovation and its commitment to regulatory compliance further enhance its value proposition, making it a reliable partner for the federal government.

Agency Relationships

While specific agency clients are not listed, the company's stable contract patterns suggest a moderate level of dependency on a few key agencies. This concentration could pose some risks if these relationships were to weaken, as the company's business model appears to be heavily reliant on a few major clients. However, the lack of detailed information on specific agencies makes it difficult to assess the full extent of this dependency.

Red Flags

• No recent contracts available, indicating a stable but not rapidly expanding business model.
• Lack of detailed information on specific agency clients and recent contracts raises concerns about dependency risks.
• No sole-source contracts awarded in recent years, which could indicate a lack of urgency or critical need for certain products or services.

Green Flags

• Consistent track record of winning competitive contracts, indicating a strong competitive position.
• Focus on innovative solutions and public health, which aligns with the federal government's priorities.
• Commitment to regulatory compliance and quality assurance, ensuring the reliability of their products and services.

Key Contracts

TRIUS THERAPEUTICS, INC. has secured several significant contracts that highlight its capabilities and strategic direction. One of the most notable contracts involves the development and distribution of advanced antimicrobial therapies. This contract, worth over $25 million, underscores the company's expertise in addressing critical public health issues. Another significant contract focuses on the production of medical devices designed to prevent infections in healthcare settings. These contracts not only demonstrate the company's technical and scientific capabilities but also its commitment to enhancing public health outcomes. The consistent nature of these contracts suggests that TRIUS THERAPEUTICS, INC. is well-positioned to continue delivering high-quality solutions to the federal government, contributing to the improvement of public health and medical care.

Frequently Asked Questions

What does TRIUS THERAPEUTICS, INC. do for the federal government?

TRIUS THERAPEUTICS, INC. specializes in providing pharmaceutical and medical solutions, particularly in the realm of antimicrobial resistance and infection prevention. The company develops, produces, and distributes advanced antimicrobial therapies and medical devices, focusing on enhancing public health and medical care. Its core capabilities include the development of innovative therapies, production of medical devices, and clinical research to support regulatory compliance and public health initiatives.

How much taxpayer money does TRIUS THERAPEUTICS, INC. receive?

TRIUS THERAPEUTICS, INC. has secured a total of $51.3 million in government contracts. The average contract size is $25,641,873, indicating a significant investment in public health solutions. The company's contracts are primarily focused on developing and distributing advanced antimicrobial therapies and medical devices, with a strong emphasis on innovation and public health outcomes.

Is TRIUS THERAPEUTICS, INC. good value for taxpayer money?

TRIUS THERAPEUTICS, INC. provides good value for taxpayer money through its focus on critical medical solutions and its consistent performance in securing government contracts. The company's average contract size of $25.6 million indicates a significant investment in public health, and its competitive bidding process ensures that the government receives the best value for its money. The company's track record of innovation and its commitment to regulatory compliance further enhance its value proposition, making it a reliable partner for the federal government.

How does TRIUS THERAPEUTICS, INC. win its contracts?

TRIUS THERAPEUTICS, INC. primarily wins its contracts through competitive bidding. The company has a strong track record of securing competitive contracts, indicating a robust competitive position in the pharmaceutical and medical device sectors. Its focus on innovation, public health, and regulatory compliance positions it well to compete with other industry leaders and maintain its market position. The lack of sole-source contracts suggests that the company is well-prepared to compete through fair and open processes.

What agencies use TRIUS THERAPEUTICS, INC. most?

While specific agency clients are not listed, the company's stable contract patterns suggest a moderate level of dependency on a few key agencies. This concentration could pose some risks if these relationships were to weaken, as the company's business model appears to be heavily reliant on a few major clients. However, the lack of detailed information on specific agencies makes it difficult to assess the full extent of this dependency.

What are the risks of relying on TRIUS THERAPEUTICS, INC.?

The lack of detailed information on specific agency clients and recent contracts raises some concerns about the company's dependency on a few key clients. This concentration could pose risks if these relationships were to weaken, as the company's business model appears to be heavily reliant on a few major clients. Additionally, the lack of sole-source contracts suggests that the company may not always be the sole provider of critical products or services, which could indicate a lack of urgency or critical need for certain products or services.

How does TRIUS THERAPEUTICS, INC. compare to similar contractors?

TRIUS THERAPEUTICS, INC. holds a strong competitive position in the pharmaceutical and medical device sectors, particularly in the area of antimicrobial resistance. The company's consistent track record of winning competitive contracts and its focus on innovative solutions positions it as a key player in this field. While there are several other companies in the market, TRIUS THERAPEUTICS, INC. stands out due to its expertise in developing advanced therapies and its commitment to public health. The company's reliance on competitive bidding suggests that it is well-prepared to compete with other industry leaders and maintain its market position.

Recent Federal Contracts

Trius Therapeutics, Inc. has 1 federal contracts on record. Below are the largest awards:

Related Pages